MED

Average revenue per active coach rose 54% year over year. Medifast ended the third quarter with $172.5 million in cash.

MED tops Q3 earnings expectations as coach productivity jumps 54.1% and margins expand, despite declining revenues and a shrinking coach network.

Medifast, Inc. (MED) Q3 2026 Earnings Call Transcript

Medifast NYSE: MED reported third-quarter 2026 revenue of $72 million, down 19.4% from a year earlier, as the company continued to face a sharp decline in its active earning coach base. Management said revenue was within its guidance range and marked a fourth consecutive quarter in which sales stabilized around the mid-$70 million range.

Medifast (MED) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.21 per share a year ago.

MED's Q3 results are likely to face pressure from GLP-1 adoption, shrinking coach numbers and lower sales, while strategic initiatives may offer some support.

Myth: Menopause weight gain is inevitable. Truth: Acceleration is not inevitable.

NUE, CNK and MED made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 14, 2026.

NATL, BGC, CCNE, FRME and UVSP have been added to the Zacks Rank #1 (Strong Buy) List on October 14, 2026.

Trilivy's™ mission is lifelong transformation through metabolic science and human connection Baltimore, MD, Oct. 13, 2026 (GLOBE NEWSWIRE) -- When every weight loss approach has failed , individuals wonder what went wrong. The answers reside in the metabolic and behavioral research, specifically in body composition science and the accountability data that explains why human support is important.